- Home
- UROY vs ITOS Comparison
UROY vs ITOS Comparison
Compare UROY & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- ITOS
- Stock Information
- Founded
- UROY 2017
- ITOS 2011
- Country
- UROY Canada
- ITOS United States
- Employees
- UROY N/A
- ITOS N/A
- Industry
- UROY
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UROY
- ITOS Health Care
- Exchange
- UROY Nasdaq
- ITOS Nasdaq
- Market Cap
- UROY 336.8M
- ITOS 381.2M
- IPO Year
- UROY N/A
- ITOS 2020
- Fundamental
- Price
- UROY $2.60
- ITOS $10.28
- Analyst Decision
- UROY Strong Buy
- ITOS Hold
- Analyst Count
- UROY 2
- ITOS 6
- Target Price
- UROY $4.00
- ITOS $10.60
- AVG Volume (30 Days)
- UROY 2.8M
- ITOS 773.7K
- Earning Date
- UROY 07-28-2025
- ITOS 08-07-2025
- Dividend Yield
- UROY N/A
- ITOS N/A
- EPS Growth
- UROY N/A
- ITOS N/A
- EPS
- UROY N/A
- ITOS N/A
- Revenue
- UROY $11,285,840.00
- ITOS $35,000,000.00
- Revenue This Year
- UROY N/A
- ITOS N/A
- Revenue Next Year
- UROY N/A
- ITOS N/A
- P/E Ratio
- UROY N/A
- ITOS N/A
- Revenue Growth
- UROY N/A
- ITOS 177.89
- 52 Week Low
- UROY $1.43
- ITOS $4.80
- 52 Week High
- UROY $3.12
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- UROY 64.77
- ITOS 65.14
- Support Level
- UROY $2.39
- ITOS $10.24
- Resistance Level
- UROY $2.54
- ITOS $10.41
- Average True Range (ATR)
- UROY 0.12
- ITOS 0.12
- MACD
- UROY 0.01
- ITOS -0.04
- Stochastic Oscillator
- UROY 99.44
- ITOS 75.00
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.